F2RL1 and fibrosarcoma: Pharmacological blockade of this factor Xa-PAR2 axis by the factor Xa inhibitor rivaroxaban has been found to decrease the risk of cancer progression in breast cancer and fibrosarcoma by promoting antitumor immunity, with efficacy comparable to that of immune checkpoint inhibition [13].